As expected market analysts IMS, Boehringer Ingelheim has managed to achieve in 2011 a growth of 8.

Home News Headlines Focus Latest Headlines File Influenza A (H1N1) Pharmaceutical Industry Product Strategy Management Biotech Releases Results Documents Policy Health Insurance Policy disease drug Hospital Medical City E-Health Public Health Medicine ovarian cysts Medical News Cancer Diabetes Alzheimer HIV Research Consumer Health Care Jobs Jobs Browse offers Recruiting Companies Submit a CV Update my CV Job Alerts Check Rates use the CV database Internships Internship offers Consult the internship offers Requests internship Post an internship offer Post request Internship Practical information - Training
During fiscal 2011, sales of German pharmaceutical company ovarian cysts Boehringer Ingelheim has increased ovarian cysts by 6.2% to 13.2 billion, after adjusting for currency effects. Over the same period, operating income also increased, standing at 2.3 billion, while the operating margin increased to 17.3%.
The company displayed excellent results especially in terms of its growth situated in the median part of a digit growth. "The results of 2011 confirm our organic growth strategy," said Andreas Barner, spokesman of the management of the company and responsible for research and development divisions and medicine at the annual press conference that s' ovarian cysts held in Ingelheim.
"Our ongoing investments in research and development ovarian cysts in-house allows us to begin a new period of growth," says Barner. Boehringer Ingelheim has achieved most of the turnover with drugs on prescription, the segment representing 77% of the ordinary activities. "The new products such as PRADAXA , but also established drugs such as Spiriva , Micardis and Combivent show a very satisfactory growth," said Hubertus von Baumbach, member of the management of the company and responsible for finance divisions and animal health.
Boehringer Ingelheim growth last year was mainly supported by the placing on the market of oral anticoagulant PRADAXA , whose turnover for 2011 amounted to 629 million. "The market launch of Pradaxa is one of the most successful in recent years in the pharmaceutical sector. "
As expected market analysts IMS, Boehringer Ingelheim has managed to achieve in 2011 a growth of 8.2% for prescription drugs, recording significantly higher ovarian cysts than the global pharmaceutical market growth, which was only 4.6%. This growth is reflected in the number of employees at the international level, enrollment increased in 2011 by 1,800 people compared to 2010, with more than 44,000 people, an increase of 4%.
With new products from its own research laboratories, the company continues to ensure the future development: "We mainly want to provide new drugs in therapeutic areas such as diabetes, oncology, hepatitis C, idiopathic pulmonary fibrosis, and respiratory diseases, "said the spokesman of the management of the company. Furthermore, the use of the active substance tiotropium in asthma, as well as new therapeutic approaches for the treatment of chronic hepatitis C and the development of Nintedanib substance for the treatment of idiopathic pulmonary fibrosis will be testing. Mr. Barner: "These new developments will allow patients to benefit from real therapeutic advances. "In order to continue to develop innovative new drugs, such as PRADAXA Trajenta and , the company continuously reinvest a significant portion of revenue in research activities and in-house development aims.
In 2011, Boehringer Ingelheim has increased spending on research and development to 2.5 billion euros (over 3%). This figure represents 23.5% of turnover with drugs on prescription. With this rate of investment, Boehringer Ingelheim far exceeds the level of the average ovarian cysts of the pharmaceutical industry.
In 2011, all areas of activities have contributed to the growth of Boehringer I